PharmaTher Holdings Ltd News

PharmaTher Updated on Its Priority Original Abbreviated New Drug Application for Ketamine

PharmaTher Holdings Ltd. (PHRM.CN), a specialty pharmaceutical company, on Tuesday provided an update on its Priority Original Abbreviated New Drug Application (ANDA) for Ketamine that was accepted by

MT NewswiresApr 16 20:39

PharmaTher's Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated...

Stockhouse Feb 21 22:30

PharmaTher Provides Update on Its Priority Original Abbreviated New Drug Application For Ketamine

PharmaTher Holdings Ltd. (PHRM.CSE), a commercial-focused specialty pharmaceutical company, on Monday provided an update on its Priority Original Abbreviated New Drug Application (ANDA) for Ketamine t

MT NewswiresFeb 12 21:43

PharmaTher Provided Update for Expected FDA Approval of Ketamine

PharmaTher Holdings Ltd. (PHRM.CSE) on Wednesday provided an update for its lead drug, ketamine (Ketarx), as a potential treatment for anesthesia, sedation, pain, mental health, and neurological indic

MT NewswiresJan 10 21:08

PharmaTher Brief: Notes FDA Assigns GDUFA Goal Date of April 29, 2024

07:34 AM EDT, 09/27/2023 (MT Newswires) -- PharmaTher Brief: Notes FDA assigns GDUFA goal date of April 29, 2024

MT NewswiresSep 27, 2023 19:34

PharmaTher Brief: Announcing FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX (Ketamine)

07:34 AM EDT, 09/27/2023 (MT Newswires) -- PharmaTher Brief: Announcing FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX (Ketamine)

MT NewswiresSep 27, 2023 19:34

PharmaTher Brief: Submitting Priority Original Abbreviated New Drug Application for KETARX (Ketamine) to FDA

07:34 AM EDT, 09/06/2023 (MT Newswires) -- PharmaTher Brief: Submitting Priority Original Abbreviated New Drug Application for KETARX (Ketamine) to FDA

MT NewswiresSep 6, 2023 19:34

PharmaDrug Announces $300,000 Strategic Investment in Sairiyo Subsidiary by PharmaTher

InvestingJul 18, 2023 20:33

PharmaTher Brief: Announcing "Positive" Research Results for PharmaPatch With N,N-dimethyltryptamine (DMT) and Strategic Investment Into Sairiyo Therapeutics

07:35 AM EDT, 07/18/2023 (MT Newswires) -- PharmaTher Brief: Announcing "Positive" Research Results for PharmaPatch with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics

MT NewswiresJul 18, 2023 19:35

Analysts Offer Insights on Healthcare Companies: PharmaTher Holdings Ltd (OtherPHRRF), Rezolute (RZLT) and ADC Therapeutics (ADCT)

TipRanksSep 19, 2022 18:40